By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Janssen Biotech Inc. 

800 Ridgeview Drive

Horsham  Pennsylvania  19044  U.S.A.
Phone: 888-227-5624 Fax: n/a


Company News
Janssen Biotech (JNJ) Release: New Data Shows STELARA (ustekinumab) Maintained Clinical Response And Remission After Two Years Of Treatment In Adult Patients With Moderately To Severely Active Crohn's Disease 2/17/2017 6:24:00 AM
X-Chem Expands Collaboration With Janssen Biotech (JNJ) In Inflammatory Diseases 2/15/2017 8:08:59 AM
Ablexis Announces Perpetual License Agreement For Alivamab Mouse With Janssen Biotech (JNJ) 2/14/2017 11:07:04 AM
Sebia Signs Agreement With Janssen Biotech (JNJ) To Develop A Multiple Myeloma IVD Test 1/30/2017 9:01:09 AM
Janssen Biotech (JNJ) Release: IMBRUVICA (Ibrutinib) Approved By FDA For Marginal Zone Lymphoma (MZL) Patients Who Require Systemic Therapy And Have Received At Least One Prior Anti-CD20-Based Therapy 1/19/2017 7:21:54 AM
Janssen Biotech (JNJ) Enters Immunotherapy Clinical Collaboration With Bristol-Myers Squibb (BMY) To Evaluate Daratumumab (DARZALEX) In Combination With Nivolumab (OPDIVO) 1/5/2017 6:21:11 AM
Janssen Biotech (JNJ) Submits Two Applications To FDA Seeking Approval Of SIMPONI ARIA (Golimumab) For The Treatment Of Active Psoriatic Arthritis And Active Ankylosing Spondylitis 12/21/2016 7:47:53 AM
Janssen Biotech (JNJ) Submits Application Seeking FDA Approval Of STELARA (Ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis 12/16/2016 7:03:00 AM
Janssen Biotech (JNJ) Submits Application To FDA Seeking Approval Of Anti-Interleukin-23 Monoclonal Antibody Guselkumab For The Treatment Of Moderate To Severe Plaque Psoriasis 11/17/2016 7:01:16 AM
Janssen Biotech (JNJ) Release: Two Studies Reveal Differences In Real-World Treatment Patterns In Rheumatoid Arthritis Patients Taking REMICAD (infliximab) Compared To CT-P13 (infliximab biosimilar) 11/14/2016 9:22:26 AM